KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Non Operating Income (2016 - 2026)

Jazz Pharmaceuticals has reported Other Non Operating Income over the past 16 years, most recently at -$658000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 89.55% year-over-year to -$658000.0; the TTM value through Dec 2025 reached -$8.6 million, down 5.72%, while the annual FY2025 figure was -$2.6 million, 68.61% up from the prior year.
  • Other Non Operating Income for Q4 2025 was -$658000.0 at Jazz Pharmaceuticals, down from $102000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $9.4 million in Q4 2023 and troughed at -$10.5 million in Q1 2022.
  • A 5-year average of -$1.3 million and a median of -$1.4 million in 2023 define the central range for Other Non Operating Income.
  • Biggest five-year swings in Other Non Operating Income: surged 735.78% in 2021 and later plummeted 1217.71% in 2022.
  • Year by year, Other Non Operating Income stood at -$5.6 million in 2021, then skyrocketed by 55.77% to -$2.5 million in 2022, then skyrocketed by 476.83% to $9.4 million in 2023, then plummeted by 167.3% to -$6.3 million in 2024, then soared by 89.55% to -$658000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for JAZZ at -$658000.0 in Q4 2025, $102000.0 in Q3 2025, and -$1.8 million in Q2 2025.